# A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors

> **NCT06544655** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 213 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** BMS-986484
- **BIOLOGICAL:** Nivolumab
- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine
- **DRUG:** Fluorouracil
- **DRUG:** Calcium folinate

## Key facts

- **NCT ID:** NCT06544655
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-10-10
- **Primary completion:** 2027-10-14
- **Final completion:** 2027-10-14
- **Target enrollment:** 213 (ESTIMATED)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06544655

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06544655, "A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06544655. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*